Skip to main content

Hereditary Angioedema

C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)
NCT00292981 | PHASE 3 | INTERVENTIONAL

Hereditary angioedema (HAE) is a rare disorder characterized by congenital lack of functional C1 esterase inhibitor. If not treated adequately, the acute attacks of HAE can be life-threatening and may even result in fatalities, especially in case of involvement of the larynx.The planned extension study is designed to enrol subjects that participated in the pivotal study in order to provide them with C1-INH for treatment of acute HAE attacks for 24 months or until the licensing procedure for C1-INH is finalized, whatever comes first.

Trial Information
14 Sites
57 Participants
Recruiting
6 Years to 17 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Contact CSL Behring for facility details
Weston,Florida,United States,33331
Contact CSL Behring for facility details
Atlanta,Georgia,United States,30342
Contact CSL Behring for facility details
Idaho Falls,Idaho,United States,83404
Contact CSL Behring for facility details
Chicago,Illinois,United States,60612
Contact CSL Behring for facility details
Shreveport,Louisiana,United States,71130
Contact CSL Behring for facility details
Boston,Massachusetts,United States,02115
Contact CSL Behring for facility details
Plymouth,Minnesota,United States,55446
Contact CSL Behring for facility details
Omaha,Nebraska,United States,69131
Contact CSL Behring for facility details
Tulsa,Oklahoma,United States,74133
Contact CSL Behring for facility details
Eugene,Oregon,United States,97401
Contact CSL Behring for facility details
Hershey,Pennsylvania,United States,17033
Contact CSL Behring for facility details
Rapid City,South Dakota,United States,57702
Contact CSL Behring for facility details
Dallas,Texas,United States,75230
Contact CSL Behring for facility details
Ottawa,Ontario,Canada,KIY4G2

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov